Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/177345
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | García Arumí, José | - |
dc.contributor.author | Gómez Ulla, Francisco | - |
dc.contributor.author | Amparo, Navea | - |
dc.contributor.author | Cervera, Enrique | - |
dc.contributor.author | Fonollosa, Alex | - |
dc.contributor.author | Arias Barquet, Lluís | - |
dc.contributor.author | Araiz, Javier | - |
dc.contributor.author | Donate, Juan | - |
dc.contributor.author | Suárez de Figueroa, Marta | - |
dc.contributor.author | Manzanas, Lucía | - |
dc.contributor.author | Crespi, Jaume | - |
dc.contributor.author | Gallego Pinazo, Roberto | - |
dc.date.accessioned | 2021-05-17T14:42:37Z | - |
dc.date.available | 2021-05-17T14:42:37Z | - |
dc.date.issued | 2018-10-14 | - |
dc.identifier.issn | 2090-004X | - |
dc.identifier.uri | http://hdl.handle.net/2445/177345 | - |
dc.description.abstract | Objectives: to evaluate efficacy and safety of an aflibercept treat-and-extend (TAE) regimen in patients with macular oedema (MO) secondary to central retinal vein occlusion (CRVO). Design setting and patients: phase IV, prospective, open-label, single-arm trial in 11 Spanish hospitals. Treatment-naïve patients with <6 month diagnosis of MO secondary to CRVO and best-corrected visual acuity (BCVA) of 73-24 ETDRS letters were included between 23 January 2015 and 17 March 2016. Intervention: intravitreal aflibercept 2 mg monthly (3 months) followed by proactive individualized dosing. Main outcomes: mean change in BCVA after 12 months. Results: 24 eyes (24 patients) were included; mean (SD) age: 62.8 (15.0) years; 54.2% male; median (IQR) time since diagnosis: 7.6 (3.0, 15.2) days. Mean BCVA scores significantly improved between baseline (56.0 (16.5)) and Month 12 (74.1 (17.6)); mean (95% CI) change: 14.8 (8.2, 21.4); P=0.0001. Twelve (50.0%) patients gained ≥15 ETDRS letters. Foveal thickness improved between baseline (mean: 569.4 (216.8) µm) and Month 12 (mean 257.4 (48.4) µm); P < 0.0001. At Month 12, 8.3% patients had MO. The mean (SD) number of injections: 8.3 (3.0). No treatment-related AEs were reported. Five (20.8%) patients experienced ocular AEs. Two nonocular serious AEs were reported. Conclusions: an aflibercept TAE regimen improves visual acuity in patients with MO secondary to CRVO over 12 months with good tolerability. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Hindawi | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1155/2018/8310350 | - |
dc.relation.ispartof | Journal of Ophthalmology, 2018, vol. 2018, p. 8310350 | - |
dc.relation.uri | https://doi.org/10.1155/2018/8310350 | - |
dc.rights | cc-by (c) García Arumí, José et al., 2018 | - |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Malalties de la retina | - |
dc.subject.classification | Edema | - |
dc.subject.classification | Estudi de casos | - |
dc.subject.other | Retinal diseases | - |
dc.subject.other | Edema | - |
dc.subject.other | Case studies | - |
dc.title | Efficacy and safety of an aflibercept treat-and-extend regimen in treatment-naive patients with macular oedema secondary to central retinal vein occlusion (CRVO): a prospective 12-month, single-arm, multicentre trial | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 695729 | - |
dc.date.updated | 2021-05-17T14:42:37Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 30405907 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
695729.pdf | 1.54 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License